



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Sprycel™

Common Name: Dasatinib

PDL Category: Antineoplastics - Protein-Tyrosine Kinase Inhibitor

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Gleevec®	Non-Recommended
Sutent®	Recommended
Velcade®	Recommended

Summary

Indications and Usage: Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) acute lymphoblastic leukemia (ALL)

Dosage Forms: Tablets, 20mg, 50mg, 70mg

Recommended Dosage: 70mg twice daily; dosing reductions likely required when used with strong CYP3A4 inhibitors and when used in patients with hematologic toxicity or nonhematologic toxicity

Common Adverse Drug Reactions: Pleural effusion, diarrhea, nausea, abdominal pain, vomiting, GI bleeding, pyrexia, febrile neutropenia, thrombocytopenia, dyspnea, anemia

Contraindications: Hypersensitivity to any component of dasatinib, pregnancy

Manufacturer: Bristol-Myers Squibb Co.

Analysis: Sprycel™ was granted accelerated approval by the FDA for adult patients being treated for CML or Ph+ALL with resistance or intolerance to prior therapy, including Gleevec®. There are no double blind, controlled studies documenting a clinical benefit with Sprycel™, such as a decrease in symptoms or decreased mortality. The approval of Sprycel™ was based on hematologic and cytogenetic response rates instead. Other formulations of tyrosine kinase inhibitors are available on the RDL that are more cost effective than Sprycel™.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input checked="" type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	